Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
System1 Biosciences has raised $25 million in series A financing for its autism, epilepsy, and schizophrenia drug discovery programs. The San Francisco-based start-up will tackle the tough-to-treat conditions by testing drugs on cerebral organoids, which are miniature brainlike organs grown in a lab. System1 is growing its organoids with stem cells from patients with a brain disease. The firm hopes that organoids will provide a more realistic preclinical model than the cells and animals often used in neuropsychiatric drug discovery.
This article has been sent to the following recipient: